1.Percutaneous transplantation of human umbilical cord-derived mesenchymal stem cells in a dog suspected to have fibrocartilaginous embolic myelopathy.
Wook Hun CHUNG ; Seon Ah PARK ; Jae Hoon LEE ; Dai Jung CHUNG ; Wo Jong YANG ; Eun Hee KANG ; Chi Bong CHOI ; Hwa Seok CHANG ; Dae Hyun KIM ; Soo Han HWANG ; Hoon HAN ; Hwi Yool KIM
Journal of Veterinary Science 2013;14(4):495-497
The use of human umbilical cord blood-derived mesenchymal stem cells for cell transplantation therapy holds great promise for repairing spinal cord injury. Here we report the first clinical trial transplantation of human umbilical cord (hUCB)-derived mesenchymal stem cells (MSCs) into the spinal cord of a dog suspected to have fibrocartilaginous embolic myelopathy (FCEM) and that experienced a loss of deep pain sensation. Locomotor functions improved following transplantation in a dog. Based on our findings, we suggest that transplantation of hUCB-derived MSCs will have beneficial therapeutic effects on FCEM patients lacking deep pain sensation.
Animals
;
Cartilage Diseases/etiology/therapy/*veterinary
;
*Cord Blood Stem Cell Transplantation/veterinary
;
Dog Diseases/etiology/*therapy
;
Dogs
;
Embolism/etiology/therapy/*veterinary
;
Female
;
Humans
;
Mesenchymal Stromal Cells/cytology/*metabolism
;
Spinal Cord Diseases/etiology/therapy/*veterinary
;
Treatment Outcome